用奥硝唑联合美沙拉嗪对溃疡性结肠炎患者进行治疗的效果探讨

Effect of Ornidazole combined with mesalazine for ulcerative colitis

目的:探讨联用奥硝唑与美沙拉嗪对溃疡性结肠炎患者进行治疗的近期疗效及其病情的远期复发情况。方法:对2013年1月至2014年1月期间四川省攀枝花市仁和区仁和医院收治的98例溃疡性结肠炎患者的临床资料进行回顾性研究。随机将这98例患者分为美沙拉嗪组和联合用药组。美沙拉嗪组中有46例患者,联合用药组中有52例患者。对美沙拉嗪组患者使用美沙拉嗪进行治疗,对联合用药组患者联用美沙拉嗪与奥硝唑进行治疗,然后比较两组患者的近期疗效、不良反应的发生率及其病情远期的复发率。结果:1)治疗2个月后,联合用药组患者治疗的总有效率为94.23%,美沙拉嗪组患者治疗的总有效率为78.26%,二者相比差异有统计学意义(P<0.05)。2)用药期间,美沙拉嗪组患者不良反应的发生率为13.46%,联合用药组患者不良反应的发生率为8.7%,二者相比差异无统计学意义(P>0.05)。3)治疗1年后,两组患者病情的复发率相比差异无统计学意义(P>0.05)。治疗1年半后,联合用药组患者病情的复发率低于美沙拉嗪组患者,差异有统计学意义(P<0.05)。治疗2年后,联合用药组患者病情的复发率低于美沙拉嗪组患者,差异有统计学意义(P<0.05)。结论:联用奥硝唑与美沙拉嗪对溃疡性结肠炎患者进行治疗的近期疗效显著,且其不良反应较少、病情远期的复发率较低。

Objective： To study effect of Ornidasole combined with mesalazine for ulcerative colitis（UC） and short-term effects and relapse state of the patients. Methods： Retrospectively study clinical material of 98 cases ulcerative colitis treated in Renhe Hospital of Renhe District of Panzhihua City of Sichuan Province from January 2013 to January 2014 for research object. Randomly divide 98 cases into study group and control group.46 cases in control group,52 cases in study group. Treat study group with Ornidazole and mesalazine ,treat control group with mesalazine, then compare short-term effects ,rate of adverse reactions and recurrence rate. Results： l）After 2 months treatment, the total effective rate （94.23%） in the experimental group was significantly higher than that in the control group （78.26%）（P 〈0.05）. 2） In the process of treatment,there were no significant differences between the total reaction rate in the experiment group （13.46%） and the control group （8.70%）（P〉 0.05）.3） 1 year after treatment, difference of recurrence rate of 2 groups has no statistical significant（P 〈0.05）. 1.5 years after treatment, recurrence rate of study group is lower than control group （ P 〉 0.05 ） .2 years after treatment, recurrence rate of study group is lower than control group （ P 〉 0.05 ） .Conclusion： Short-term effects of therapy of Ornidasole combined with mesalazine for ulcerative colitis is obviously with less adverse reactions.